ATX-GD-59 (a combination of two TSHR peptides) was evaluated in a phase 1 study of 12 patients with previously untreated mild-to-moderate Graves’ hyperthyroidism, receiving 10 doses of ATX-GD-59 intradermally over an 18-week period [127]. Here, TSHR is linked to Graves disease.